CINECA IRIS Institutional Research Information System

GIANI, CARLOTTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.776
EU - Europa 1.981
AS - Asia 1.975
SA - Sud America 330
AF - Africa 126
OC - Oceania 8
Totale 8.196
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.677
SG - Singapore 670
CN - Cina 515
IT - Italia 497
DE - Germania 479
SE - Svezia 316
HK - Hong Kong 296
BR - Brasile 277
VN - Vietnam 175
GB - Regno Unito 172
BG - Bulgaria 121
AT - Austria 92
FR - Francia 79
RU - Federazione Russa 68
JP - Giappone 66
CA - Canada 60
CI - Costa d'Avorio 54
IN - India 53
FI - Finlandia 42
TR - Turchia 38
SN - Senegal 36
BD - Bangladesh 27
NL - Olanda 25
IQ - Iraq 21
AR - Argentina 19
MX - Messico 19
PK - Pakistan 18
MA - Marocco 14
PH - Filippine 13
PL - Polonia 13
ID - Indonesia 11
SA - Arabia Saudita 11
IR - Iran 10
KR - Corea 10
UZ - Uzbekistan 10
CO - Colombia 9
CZ - Repubblica Ceca 9
EC - Ecuador 9
UA - Ucraina 9
ZA - Sudafrica 9
AU - Australia 7
CH - Svizzera 7
ES - Italia 7
VE - Venezuela 7
IE - Irlanda 6
BE - Belgio 5
IL - Israele 5
LT - Lituania 5
PT - Portogallo 5
RO - Romania 5
AL - Albania 4
MY - Malesia 4
SK - Slovacchia (Repubblica Slovacca) 4
TT - Trinidad e Tobago 4
TW - Taiwan 4
CL - Cile 3
HN - Honduras 3
JM - Giamaica 3
PA - Panama 3
TN - Tunisia 3
UY - Uruguay 3
AZ - Azerbaigian 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
EE - Estonia 2
EG - Egitto 2
ET - Etiopia 2
GR - Grecia 2
IS - Islanda 2
JO - Giordania 2
KE - Kenya 2
KZ - Kazakistan 2
LB - Libano 2
NG - Nigeria 2
NP - Nepal 2
PE - Perù 2
AE - Emirati Arabi Uniti 1
BH - Bahrain 1
BO - Bolivia 1
BY - Bielorussia 1
CR - Costa Rica 1
DM - Dominica 1
GD - Grenada 1
GT - Guatemala 1
HR - Croazia 1
KG - Kirghizistan 1
LV - Lettonia 1
MM - Myanmar 1
MN - Mongolia 1
NZ - Nuova Zelanda 1
OM - Oman 1
PS - Palestinian Territory 1
QA - Qatar 1
VG - Isole Vergini Britanniche 1
Totale 8.196
Salva come PNG Salva come JPEG
Città #
Ashburn 526
Singapore 364
Chandler 295
Hong Kong 292
San Jose 237
Santa Clara 236
Dallas 231
Fairfield 224
Woodbridge 198
Milan 196
Shanghai 132
Houston 130
Sofia 121
Seattle 117
Wilmington 101
New York 95
Beijing 91
Vienna 89
Los Angeles 87
Cambridge 78
London 73
Princeton 73
Boardman 61
Ann Arbor 59
Munich 57
Abidjan 54
Tokyo 54
Lawrence 50
Florence 49
Lauterbourg 47
Frankfurt am Main 44
Ho Chi Minh City 43
Medford 41
Dakar 36
Rome 30
Council Bluffs 28
Serra 28
Helsinki 24
Ottawa 24
Boulder 23
Bremen 23
Redmond 23
São Paulo 23
Dong Ket 22
Hanoi 22
San Diego 21
Redondo Beach 20
Dearborn 19
Pisa 19
Des Moines 15
Hefei 15
Istanbul 15
Nanjing 15
Redwood City 15
Washington 15
Amsterdam 14
Buffalo 14
Belo Horizonte 13
Fuzhou 13
Nuremberg 12
Orem 12
Baghdad 11
Phoenix 11
Warsaw 11
Montreal 10
Toronto 10
Denver 9
Dhaka 9
Haiphong 9
Rio de Janeiro 9
Turku 9
Atlanta 8
Düsseldorf 8
Stockholm 8
Tashkent 8
Tianjin 8
Brno 7
Chicago 7
Da Nang 7
Guangzhou 7
Izmir 7
Lancaster 7
Nanchang 7
Norwalk 7
Ogden 7
Salt Lake City 7
Seoul 7
Casablanca 6
Cleveland 6
Dublin 6
Quanzhou 6
San Francisco 6
Scandicci 6
Shenyang 6
Ankara 5
Boston 5
Changsha 5
Chiesina Uzzanese 5
Columbus 5
Fortaleza 5
Totale 5.385
Salva come PNG Salva come JPEG
Nome #
Treatment of advanced thyroid cancer with targeted therapies: Ten years of experience 244
Modifications in the Papillary Thyroid Cancer Gene Profile Over the Last 15 Years. 241
Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at one single Italian center 233
Targeted Therapy in Thyroid Cancer: State of the Art 224
A complex MEN2 syndrome, a mixture of 2B and 2A, associated with a new RET germiline deletion. 223
Hypertension, nausea, anorexia and weight loss were significantly associated with better progression-free survival in patients with radioiodine-Refractory Differentiated Thyroid Carcinoma treated with Lenvatinib 217
Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations 214
Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life 209
Next generation sequencing revealed RET or RAS mutation in medullary thyroid cancer that were negative at sanger sequencing 205
Nuove indicazioni all’impiego del TSH umano ricombinante (rhTSH) e basse attività di 131I nella radioablazione del residuo tiroideo post-chirurgico. 204
Lenvatinib therapy in progressive, radioiodine-refractory, differentiated thyroid carcinoma: analysis of 74 cases followed in a single centre 196
Il carcinoma tiroideo: nuove prospettive terapeutiche. 191
Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer 190
Successo terapeutico di Lenvatinib in seconda linea in un caso di carcinoma follicolare della tiroide avanzato 189
Outcome of classical (CVPTC) and follicular (FVPTC) variants of papillary thyroid cancer: 15 years of follow-up 183
Fifty years after the first description, the MEN 2B syndrome diagnosisis still late: description of two recent cases 177
Thyroid cancers: From surgery to current and future systemic therapies through their molecular identities 177
Radio-iodine refractory thyroid cancer patients: a tailored follow-up based on clinicopathological features 171
5 YEARS FOLLOW UP OF THYROGLOBULIN (TG), THYROGLOBULIN ANTIBODIES (TGAB) AND NECK ULTRASOUND (US) IN PATIENTS WITH PAPILLARY THYROID MICROCARCINOMA (MPTC) TREATED WITH TOTAL THYROIDECTOMY BUT NOT ABLATED WITH 131I 171
Lenvatinib treatment in the real clinical practice of progressive, radioiodine-refractory differentiated thyroid carcinoma: analysis of a big series followed in a single center 170
MON-524 Prospective Evaluation of Patients with Encapsulated Classical Variant of Papillary Thyroid Cancer and Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP): Have They A Similar Prognosis? 170
A rare adverse event (AE) in a group of radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients in therapy with lenvatinib. 164
Modifications in the Papillary Thyroid Cancer Gene Profile Over the Last 15 Years. 163
MON-490 Calcitonin-Based Thyroidectomy Is a Safe Approach in Patients with Germline RET Mutation and Permits to Delay Surgery in Children 162
No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSH 161
OR21-01 Pre-Operative Calcitonin Value as a Predictive Factor of Cancer Related Death in Sporadic Medullary Thyroid Carcinoma 156
Fenotipo misto MEN2A/MEN2B da nuova mutazione germinale di RET: prima descrizione clinico-genetica e iconografia 152
5 Years Follow Up Of Thyroglobulin (Tg), Thyroglobulin Antibodies (Tgab) And Neck Ultrasound (Nus) In Patients With Papillary Thyroid Microcarcinoma (Mptc) Treated With Total Thyroidectomy But Not Ablated With 131I 149
Whole Tumor Capsule Is Prognostic of Very Good Outcome in the Classical Variant of Papillary Thyroid Cancer 145
A Patient with Advanced Medullary Thyroid Cancer and Progressive Symptomatic Distant Metastases: When to Start Systemic Therapy 136
Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer 136
Radioiodine remnant ablation (RRA) Impact on the dynamic risk of restratification in the short-term follow-up of patients with differentiated thyroid cancer (DTC). 133
The outcome of metastatic differentiated thyroid cancer is similar in patients prepared for 131-I therapy with recombinant TSH or Hypothyroidism. 133
Impact of the Stimulation method Used for 131-Therapy in Patients With Differentiated Thyroid Cancer. 129
Re: "Symptomatic Biliary Disorders During Lenvatinib Treatment for Thyroid Cancer: An Underestimated Problem" by Nervo et al 128
Thyroid cancer and COVID-19: experience at one single thyroid disease referral center 127
Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid Cancer 126
Correlation of the presurgical diagnosis of follicular variant of papillary thyroid cancer with the disease status after 10 years of follow-up. 125
The Integrity of Tumor Capsule Identifies a Subgroup of Indolent Cases Not Only Among the Follicular (FVPTC) But Also in Classic Variant of Papillary Thyroid Cancer (CVPTC) 124
Minimally invasive video-assisted thyroidectomy versus conventional thyroidectomy in pediatric patients 122
Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer 118
MON-537 Primary Adrenal Insufficiency During Tyrosine Kinase Inhibitors Treatment in Advanced Thyroid Cancer Patients 117
Follicular (FVPTC) VS Classical (CVPTC) variant of papillary thyroid cancer: correlation of the outcome after 12 years of follow up. 116
null 105
Correction to: Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer (Journal of Endocrinological Investigation, (2021), 44, 10, (2139-2151), 10.1007/s40618-020-01491-3) 104
Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up. 101
KIF5B/RET rearrangement in diffuse sclerosing variant of papillary thyroid cancer (DSV-PTC) 97
The macrofollicular variant of papillary thyroid cancer (MF-PTC): a bicentric retrospective analysis of 65 cases. 93
Pre-surgical Value Of Basal Calcitonin Is Not Predictive Of Central Neck Compartment Metastases. 92
null 86
Medullary thyroid cancer secreting carbohydrate antigen 19-9 (Ca 19-9): a fatal case report. 74
null 70
Pros and cons of an aggressive initial treatment with surgery and radioiodine treatment in minimally invasive follicular thyroid carcinoma 65
Postoperative thyroglobulin and neck ultrasound in the risk restratification and decision to perform ¹³¹l ablation 63
The Macrofollicular Variant of Papillary Thyroid Cancer: a retrospective analysis of 30 cases from a Single Centre. 56
Fifty Years after the First Description, MEN 2B Syndrome Diagnosis Is Still Late: Descriptions of Two Recent Cases 54
A patient with an advanced medullary thyroid cancer and progressive, symptomatic distant metastases: When to start systemic therapy 30
Gender impact on safety and efficacy in lenvatinib treated patients with radioiodine-refractory differentiated thyroid cancer (GISEL study) 3
Totale 8.314
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.963
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.963
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202176 0 0 0 0 0 0 0 0 0 0 0 76
2021/2022574 13 14 11 27 111 86 6 24 34 38 51 159
2022/20231.107 137 183 88 94 102 124 14 79 189 12 80 5
2023/2024712 65 79 104 64 111 124 26 10 6 8 41 74
2024/20251.841 16 69 11 93 207 181 137 90 204 231 181 421
2025/20262.252 223 298 212 224 271 153 323 100 153 199 78 18
Totale 8.314